Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group
Sarah Bertoli,
Pierre Bories,
Marie C. Béné,
Sylvie Daliphard,
Bruno Lioure,
Arnaud Pigneux,
Norbert Vey,
Jacques Delaunay,
Vincent Leymarie,
Isabelle Luquet,
Odile Blanchet,
Pascale Cornillet-Lefebvre,
Mathilde Hunault,
Didier Bouscary,
Nathalie Fegueux,
Philippe Guardiola,
François Dreyfus,
Jean Luc Harousseau,
Jean Yves Cahn,
Norbert Ifrah,
Christian Récher
Affiliations
Sarah Bertoli
Service d’Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Université Paul Sabatier, Toulouse
Pierre Bories
Service d’Hématologie, Hôpitaux Universitaires de Strasbourg
Marie C. Béné
Laboratoire d’Hématologie, CHU de Nantes
Sylvie Daliphard
Laboratoire d’Hématologie, CHU de Reims
Bruno Lioure
Service d’Hématologie, Hôpitaux Universitaires de Strasbourg
Arnaud Pigneux
Service d’Hématologie, CHU de Bordeaux
Norbert Vey
Service d’Hématologie, Institut Paoli-Calmettes, Marseille
Jacques Delaunay
Service d’Hématologie, CHU de Nantes
Vincent Leymarie
Laboratoire d’Hématologie, Hôpitaux Universitaires de Strasbourg
Isabelle Luquet
Laboratoire d’Hématologie, CHU de Reims
Odile Blanchet
Laboratoire d’Hématologie, CHU de Toulouse
Pascale Cornillet-Lefebvre
Laboratoire d’Hématologie, CHU de Reims, France
Mathilde Hunault
Service d’Hématologie, CHU d’Angers
Didier Bouscary
Service d’Hématologie, APHP Cochin, Paris
Nathalie Fegueux
Service d’Hématologie, CHU de Montpellier
Philippe Guardiola
Service d’Hématologie, CHU d’Angers
François Dreyfus
Service d’Hématologie, APHP Cochin, Paris
Jean Luc Harousseau
Service d’Hématologie, Institut de Cancérologie de l’Ouest, Centre René Gauducheau, Nantes St Herblain
Jean Yves Cahn
Clinique Universitaire d’Hématologie, CHU de Grenoble, France
Norbert Ifrah
Service d’Hématologie, CHU d’Angers
Christian Récher
Service d’Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Université Paul Sabatier, Toulouse
Early response to chemotherapy has a major prognostic impact in acute myeloid leukemia patients treated with a double induction strategy. Less is known about patients treated with standard-dose cytarabine and anthracycline. We designed a risk-adapted remission induction regimen in which a second course of intermediate-dose cytarabine was delivered after standard “7+3” only if patients had 5% or more bone marrow blasts 15 days after chemotherapy initiation (d15-blasts). Of 823 included patients, 795 (96.6%) were evaluable. Five hundred and forty-five patients (68.6%) had less than 5% d15-blasts. Predictive factors for high d15-blasts were white blood cell count (P
